Urinary FABP1 levels in radiocontrast medium (RCM)-induced AKI. Urinary FABP1 measurement of 66 patients who had a serum creatinine level >1.2 mg/dl (>106 μmol/l) and
Fig. 5.
Correlation of urinary markers and…
Fig. 5.
Correlation of urinary markers and tubulointerstitial injury. Correlations between urinary markers [protein (…
Fig. 5. Correlation of urinary markers and tubulointerstitial injury. Correlations between urinary markers [protein (top), NAG (middle), and FABP1 (bottom)] and fibrotic area and F4/80 positively stained area in adenine-induced tubulointerstitial injury model are shown. •, Adenine diet group; ▴, treatment group; ○, normal diet group. Original data from Tanaka et al. (49).
Fig. 6.
Urinary FABP1 levels of responders…
Fig. 6.
Urinary FABP1 levels of responders and nonresponders in cyclooxygenase 2 (COX2) inhibitor-induced tubulointerstitial…
Fig. 6. Urinary FABP1 levels of responders and nonresponders in cyclooxygenase 2 (COX2) inhibitor-induced tubulointerstitial injury model. A: COX2 inhibitor-induced low peritubular capillary blood flow determined the animals as responders or nonresponders. B: responders (urinary FABP1 >50 μg/g creatinine) showed larger interstitial fibrosis area than nonresponders (<50 μg/g creatinine). Original data from Tanaka et al. (50). Quantitative analysis was performed by the computer-aided evaluation program AIS (Fujifilm, Tokyo, Japan). Asterisk denotes P < 0.05.
Fig. 7.
Correlations between urinary FABP1 level…
Fig. 7.
Correlations between urinary FABP1 level and peritubular capillary blood flow and ischemia time…
Fig. 7. Correlations between urinary FABP1 level and peritubular capillary blood flow and ischemia time of the transplanted kidney. Urinary FABP1 was compared with 1/blood flow (A) and ischemia time (B). Where renal ischemia is more severe, 1/blood flow is larger. The ischemic time in living-related renal transplantation was defined as the period between the clamp of the donor's renal artery and the appearance of virgin urine from the recipient's ureter. Original data from Yamamoto et al. (60).
Fig. 8.
Double immunostaining of human (h)FABP1…
Fig. 8.
Double immunostaining of human (h)FABP1 and 4-hydroxyhexenal (HHE) in animal AKI models. Double…
Fig. 8. Double immunostaining of human (h)FABP1 and 4-hydroxyhexenal (HHE) in animal AKI models. Double immunostaining of hFABP1 (brown) and HHE (purple) in I/R-AKI (A) and CP-AKI (B) is shown. HHE accumulation was found in severely damaged tubular cells, and relatively preserved tubular cells showed positive staining of FABP1. Original data partly from Negishi et al. (36).
Fig. 9.
Urinary FABP1, plasma FABP1, and…
Fig. 9.
Urinary FABP1, plasma FABP1, and urine-to-plasma ratio of FABP1 in CP-AKI mice. Urinary…
Fig. 9. Urinary FABP1, plasma FABP1, and urine-to-plasma ratio of FABP1 in CP-AKI mice. Urinary and plasma FABP1 levels were examined in CP-AKI (20 mg/kg). Urine and plasma levels of hFABP1 increased after CP injection. However, urinary level was much higher than plasma level and urine-to-plasma ratio increased >25-fold compared with 0 h. Original data from Negishi et al. (36).
Fig. 10.
A strategy for biomarker development.…
Fig. 10.
A strategy for biomarker development. CKD, chronic kidney disease; LPS, lipopolysaccharide; CLP, cecal…
Fig. 10. A strategy for biomarker development. CKD, chronic kidney disease; LPS, lipopolysaccharide; CLP, cecal ligation and puncture; CPB, cardiopulmonary bypass; UUO, unilateral ureter obligation; Alb, albumin; FGS, focal glomerulosclerosis; DM diabetes mellitus; IgAN, IgA nephropathy.